Understanding how peptides are dosed in published research — and why this often differs substantially from protocols that circulate in online communities — is essential context for evaluating any claim about peptide efficacy or safety. This article provides an educational examination of peptide dosing principles as they appear in the peer-reviewed literature, contrasting research methodology with the anecdotal approaches that often dominate public discussion.
This content is strictly educational. It does not constitute medical advice or dosing recommendations for any compound. Specific dosing decisions for any peptide should only be made in consultation with a qualified healthcare provider, and only for compounds that are legally and medically appropriate in a given individual's circumstances.
How Research Protocols Approach Dosing
The IND Process and Dose Escalation Studies
In formal clinical research, dosing is determined through a structured development process. Phase 1 clinical trials — the first-in-human studies — are specifically designed to establish safety and tolerability, beginning with doses far below estimated therapeutic levels and escalating cautiously. This process is governed by regulatory frameworks and ethics committee oversight.
For many peptides in the research space, this formal development process is incomplete or absent. BPC-157, for example, has an extensive preclinical (animal) literature but has not completed a formal dose-escalation phase 1 trial with published results available in mainstream literature as of 2026. This means that the doses circulating in community discussions are not derived from FDA-reviewed safety data but from extrapolations from animal studies and empirical reports.
Allometric Scaling: Translating Animal Doses to Humans
When animal study doses are discussed in human contexts, a method called allometric scaling is often applied. This approach accounts for the fact that smaller animals have higher metabolic rates per unit of body weight than larger animals, meaning that equivalent biological effects often require proportionally higher doses per kilogram in smaller species. The most commonly used scaling factor for translating rodent doses to human-equivalent doses is 0.081 — meaning one would multiply the rat dose (in mg/kg) by 0.081 to estimate a human-equivalent dose.
For example, if a rat study used 10 mcg/kg of BPC-157, the rough human-equivalent dose calculation would be approximately 0.81 mcg/kg. For a 70 kg human, that would translate to approximately 57 mcg. However, it is critical to understand that allometric scaling is an approximation with significant uncertainty — it assumes similar pharmacokinetic and pharmacodynamic properties across species, which may not hold for all peptides. Differences in receptor density, blood-brain barrier permeability, first-pass metabolism, and protein binding can all cause actual human effective doses to differ substantially from allometrically scaled estimates.
Weight-Based vs. Fixed Dosing in Clinical Research
Clinical research protocols may use either weight-based dosing (expressed as dose per kilogram of body weight, e.g., mcg/kg) or fixed dosing (a single dose applied regardless of weight, e.g., a flat 300 mcg). The choice between these approaches depends on the pharmacokinetic properties of the compound and the therapeutic objectives.
Weight-based dosing is more common in phase 1 and early phase 2 trials, where the goal is to characterize the dose-response relationship across individuals with different body compositions and metabolic characteristics. It is also common for peptides where pharmacokinetic data suggests significant variation in distribution volume or clearance with body size.
Fixed dosing becomes more common in later phase trials for compounds where population pharmacokinetic analyses have shown that individual weight variation does not substantially alter drug exposure at therapeutic doses. Semaglutide, for example, is prescribed as a fixed weekly dose regardless of patient weight.
For research peptides lacking formal pharmacokinetic characterization in humans, neither approach can be definitively validated. Community protocols typically use fixed doses based on empirical experience rather than pharmacokinetically informed dosing.
Specific Examples From Published Literature
Tesamorelin (FDA-Approved GHRH Analogue)
Tesamorelin (Egrifta) provides one of the most instructive examples because it is an FDA-approved GHRH analogue with published, validated clinical trial data. The approved dose for HIV-associated lipodystrophy is 2 mg administered subcutaneously once daily. This fixed dose was determined through clinical trials — specifically the LIPO-010 and LIPO-011 trials published in the New England Journal of Medicine (Falutz et al., 2007, 2010) — that examined different doses and established the efficacy/safety profile at 2 mg.
This dose was not derived from allometric scaling from rat studies alone but was validated in adequately powered human trials. The process took years and involved careful examination of GH/IGF-1 responses, metabolic effects, and adverse event profiles across hundreds of patients.
Semaglutide Dose Escalation
The approved semaglutide protocol for obesity management (Wegovy) uses a gradual dose escalation: 0.25 mg weekly for 4 weeks, then 0.5 mg for 4 weeks, then 1.0 mg for 4 weeks, then 1.7 mg for 4 weeks, then 2.4 mg as the maintenance dose. This structured titration was determined through clinical trial data showing that rapid dose escalation dramatically increases gastrointestinal side effects, while gradual escalation allows accommodation and improves tolerability without sacrificing long-term efficacy.
This example illustrates how clinical research doesn't just determine the effective dose but also the optimal approach to reaching that dose — information that is often absent from research-compound protocols where formal titration studies have not been conducted.
BPC-157 in Animal Studies
Published BPC-157 animal studies have used a range of doses. Studies by Sikiric and colleagues have examined doses ranging from approximately 10 mcg/kg to 10 mg/kg in rats, with various routes of administration (subcutaneous, intraperitoneal, oral). Applying allometric scaling, the 10 mcg/kg rat dose would suggest a human-equivalent of approximately 0.81 mcg/kg, while the 10 mg/kg dose would suggest approximately 810 mcg/kg — a range of over 1,000-fold. This wide range across the published literature highlights why allometric scaling alone is insufficient to determine appropriate human doses for compounds that lack validated human pharmacokinetic data.
The Anecdotal Protocol Gap
Community peptide protocols frequently cite doses and schedules that may differ substantially from what published research supports. Common sources of divergence include:
- Species confusion: Direct application of rat mg/kg doses to humans without scaling, which would result in doses dramatically higher than human-equivalent estimates.
- Vendor recommendations: Commercial sources may suggest doses based on sales optimization rather than clinical evidence.
- Forum extrapolation: Individual anecdotal reports of "what worked" circulate and compound, creating the appearance of consensus around particular doses without underlying evidence.
- Conflation with different compounds: Protocols may reference findings from chemically related but distinct peptides as if they are interchangeable.
None of this means that anecdotal protocols are necessarily harmful, but it does mean that their evidence basis is fundamentally different from — and generally weaker than — clinically derived protocols. Efficacy and safety claims based on anecdotal community experience should not be treated as equivalent to clinical trial evidence.
Route of Administration and Its Impact on Dosing
The route of administration profoundly affects how much of a peptide reaches systemic circulation and, therefore, what dose is needed for a given effect. For most peptides, the relevant routes are:
- Subcutaneous injection: Absorption is generally good for small to medium peptides, with bioavailability typically ranging from 40–90% depending on the compound's characteristics. This is the most common route in peptide research.
- Intramuscular injection: Generally similar to subcutaneous for most peptides, with potentially faster onset for some compounds.
- Oral administration: Most peptides are significantly degraded in the gastrointestinal tract by peptidase enzymes and stomach acid. Bioavailability is typically very low (often under 5% for unmodified peptides). Claims about oral peptide bioavailability require specific supporting data — it is not appropriate to assume oral and injectable doses are equivalent.
- Intranasal administration: Some smaller peptides can achieve meaningful systemic absorption via nasal mucosa. Semax and Selank, for example, are commercially administered as nasal sprays in Russia. The nasal route bypasses first-pass hepatic metabolism and provides a relatively non-invasive alternative to injection for appropriately small peptides.
Monitoring Parameters in Research Protocols
Formal research protocols typically specify laboratory monitoring parameters alongside dosing. For GH secretagogues, this commonly includes IGF-1 levels as a marker of GH axis activity. For GLP-1 agonists in metabolic contexts, blood glucose, HbA1c, lipid panels, and kidney function may be monitored. This monitoring serves both to document efficacy (does the biomarker change as expected?) and to detect emerging safety signals.
Community peptide protocols often lack this monitoring component, which represents a meaningful difference from clinical research practice. Without monitoring, it is difficult to know whether a given protocol is achieving its intended biological effect or whether subtle safety signals are being missed.
Medical Disclaimer
This article is provided for educational and informational purposes only. The dosing information and methodology discussed here is drawn from published research literature for the purpose of explaining how clinical research approaches are structured. Nothing in this article should be interpreted as a dosing recommendation for any peptide or as guidance for self-administration of any compound. Peptide dosing in clinical contexts requires individualized medical assessment, appropriate laboratory monitoring, and ongoing medical supervision. Most peptides discussed in research and community contexts have not received FDA approval for the uses described, and using them outside of approved clinical protocols carries risks that are not fully characterized by existing data.